Market leading insight for tax experts
View online issue

Vaccine Research: trading divided

Speed read

Recent cases such as Tower MCashback and Icebreaker have considered whether, in reality, a taxpayer incurred expenditure ‘on’ an asset or activity in a manner which qualified for tax relief. In Vaccine Research Limited Partnership, the First-tier Tribunal has decided that a partnership did not incur most of its expenditure ‘on’ research and development, thereby denying the majority of its claim for capital allowances. But in doing so, the tribunal took the odd decision to dissect the partnership’s business into trading and non-trading activities, and it left open the characterisation of the partnership’s non-trading receipts. 

If you or your firm subscribes to Taxjournal.com, please click the login box below:

If you do not subscribe but are a registered user, please enter your details in the following boxes:

Alternatively, you can register free of charge to read a limited amount of subscriber content per month.
Once you have registered, you will receive an email directing you back to read this article in full.
Please reach out to customer services at +44 (0) 330 161 1234 or 'customer.services@lexisnexis.co.uk' for further assistance.
EDITOR'S PICKstar
Top